Dear Tamar,

 

The stock is released and in Dublin so Ben can start preparing the shipping docs for you.

 

Lot	P/N	Org	Location	Product	Details	Mfg Date	Exp Date	Status	QoH
WMWSD	61958-1802-6	127	Dublin	Harvoni	GAP Rott/Tro v6	16-Jul-16	31-Jul-21	Release	9215

 

Regards,

Sean

 

 

Dear Ben,

 

I hope all is well with you. I am writing to enquire about the status if the Harvoni order placed on August 6^th . May I kindly ask what’s anticipated delivery date. Our current stock for Harvoni is nearly exhausted and would be good to know when drugs arrive.

Many thanks!

 

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

 

Sincerely,

Tamar Gabunia, MD, MPH

Deputy Minister

 

 

 

 

 

Dear Tamar

 

Thank you for your order. 

 

Please note the standard lead time for an order is 60 days to accommodate resource and material planning but where possible we will look to expedite.  A Gilead packaging slip, Certificate of Analysis (COA) and other relevant shipping documentation will be provided at the earliest opportunity.  

 

 

Best Regards,

 

Ben Dunne

Supply Chain Specialist III

Gilead Sciences Ireland UC

Eagle House

Elm Road

Dublin Airport Logistics Park

St. Margaret’s

Co. Dublin

K67 W240

Ireland

Direct phone: +353 1 2913571

Fax number:  +353 1 2944031

e-mail: ben.dunne@gilead.com

 

 

 

 

 

Dear Ben

I hope all is well with you. With this I would like to place the Harvoni order ( on 5000 bottles). Should you have any questions or require clarification please kindly let me know.

 

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

 

Sincerely,

Tamar Gabunia, MD, MPH

Deputy Minister

 

 

 

 

Hi Tamar,

 

We have approx. 7200 units in stock. Would a partial shipment of 7200 units this week suffice and we can ship the balance next week?

 

Ive just heard there is a small delay on the line running the balance of approx. 2800 units.  

 

Thanks

Ben

 

 

Dear Ben

Many thanks for your prompt reply. Much appreciated!

 

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

 

Sincerely,

Tamar Gabunia, MD, MPH

Deputy Minister

 

 

 

 

 

Hello Tamar,

 

We are planning to dispatch on Friday (we are expecting the balance of stock from our manufacturing site tomorrow), i have requested flight details and will forward them to you later today.

 

Best Regards

Ben

 

 

Dear David

 

I am writing back regarding the Epclusa order status. May I kindly ask what’s an estimated delivery date to Georgia? Our current stock of the drug is really low and we need to plan carefully before drugs arrive.

Many thanks for your understanding and cooperation.

 

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

 

Sincerely,

Tamar Gabunia, MD, MPH

Deputy Minister

 

 

 

 

 

Dear Tamar,

 

This is excellent news.

We will check the status of Epclusa and get back to you.

 

Have a great weekend,

David

 

 

Dear David,

Thanks for your reply. We expect to utilize the existing Harvoni stock before its expiry date, based on the assumption that the current enrollment rate is maintained/increased. Will provide the order as advised and can received the order as it becomes available.

I would like to take this opportunity and check with you the Epclusa order status. We are hoping to receive it by the end of June.

Many thanks for all your assistance.

 

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

 

Sincerely,

Tamar Gabunia, MD, MPH

Deputy Minister

 

 

 

 

 

Dear Tamar,

 

Thank you very much for the detailed update.

If I understand correctly, you might be able to fully use the existing Harvoni stock before its expiry date?

 

Please place the Harvoni order for the additional 7220 bottles, we will trigger the appropriate activities once received.

In case the product becomes available earlier, would you like to receive it before September?

 

Best regards,

David

 

 

Dear Sean

I hope all is well with you. With this I would like to provide you with updated information on HCV Program implementation and share our estimates on the needed amount of Harvoni.

In general, from the beginning of the HCV program implementation more then 55 000 HCV patients were registered, more then 54 000 out of registered patients have already started treatment and more than 51 000 completed treatment.

As you have already been informed, at this stage, we have patients on both treatment regimens, with Epclusa and with Harvoni; monthly registration in the program is stable, with about 1000 -1100 patient (about 54% of patients are on treatment with epclusa regimens and 46% on harvoni regimens). The number of patients enrolled on Harvoni treatment is around 470-500 monthly. We think we will maintain the current enrolment on Harvoni in the coming months.

With this picture of inflow, from June, until the end of the year, about 3500 new patients will be included in HCV program with Harvoni regimens. The needed amount of Harvoni for current and new patients is around  11150 bottles. It should be noted that the current stock of Harvoni is 6930 bottles with the expiry date on December 31st. The total need of Harvoni (including the three months buffer stock (additional 3000 bottles)) by the end of 2019 amounts to 7220 bottles.

Please kindly let us know if you have any questions or concerns on these estimates. If acceptable, we will provide an official order for 7220 Harvoni bottles in the next few days.

Many thanks and look forward to hearing from you.

With Kind Regards,

 

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

 

Sincerely,

Tamar Gabunia, MD, MPH

Deputy Minister

 

 

 

 

 

Dear Tamar,

 

Greetings to you as well and many thanks for this comprehensive update.  I’m glad to see the Epclusa rollout is progressing as planned.  Yes, please go ahead and place an order for 11,000 Epclusa bottles.

 

Regarding Harvoni, I suggest we tentatively plan a packaging run of 3,000 to 5,000 bottles for delivery in September, to give you enough time to replace the expiring product in November.  Let’s try to make sure you have enough to cover Q1 ’20 demand as well.  For all bottles expiring, we’ll need proof of destruction when the time comes. 

 

Regards,

Sean

 

 

Dear Sean

Greetings! With this I would like to provide you with updated information on HCV Program and adjusted plan on treatment.

From the beginning of the HCV program implementation more then 55 000 HCV patients were registered, more then 54 000 out of registered patients have already started treatment and more than 50 000 completed treatment.

As you have already been informed, at this moment, we have patients on both treatment regimens, with Epclusa and with Harvoni;

·         From December 2018, we included Epclusa in treatment regimens for all untreated (treatment naïve) or already treated (treatment experienced) patients with genotype 2 and 3, also, for already treated (treatment experienced) patients with genotype 1 and 4. For all other patients we used Harvoni regimens.

·         Currently, the number of patients receiving Epclusa treatment regimens is about 550 per month and with Harvoni treatment regimens - about 500 per month.

·         With this picture of inflow, from now, until the end of the year, about 4950 new patients will be enrolled in HCV program on Epclusa containing regimens, out of them about 88% will be on 12-week regimens and 12% on 24-week treatment regimens. To provide medicines for this group of patients, we will need about 17 400-bottles of Epclusa, by the end of the year. It should be noted that at the moment the number of Epclusa bottles remaining in central warehouse is about 6400, so the total number of required bottles is 11 000 bottles (=17400-6400).

If our request is acceptable, we will provide an official order for 11000 Epclusa bottles in the next few days.

 

As for Harvoni, at the moment number of bottles, remaining at the warehouse is enough for about 6 months (the estimated number of patients 500 per month on average). We estimate that 14000 bottles of Harvoni will be needed in April-December. Currently the available stock includes 10550 bottles with the expiry date on December 31, 2019. We would appreciate your guidance on managing the available stock  given the anticipated expiry by the end of 2019.  

Many thanks and look forward to hearing from you.

With Kind Regards,

Tamar Gabunia

Deputy Minister  

 

 

Dear Tamar,

 

Thank you and nice to meet you.  I look forward to the update.

 

Regards,

Sean

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England